Phase 2 N=3 Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 2 N=4 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants
N/A N=100 Melanoma Perception and Health Literacy in People of Color
Melanoma
Primary: Number of Participants That Performed Regular Self-Skin Examinations — 8; 16; 23; 25 participants — p=0.048
Phase 2 N=104 Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
High-Risk Melanoma
Primary: Immunologic Response Rate — 2; 0; 0; 3 Participants
Phase 1 N=15 A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Melanoma
Primary: Number of Participants Experiencing Clinical and/or Laboratory Dose-limiting Toxicities — 0 Participants
N/A N=75,771 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Vitiligo · Melanoma (Skin) · Nonmelanoma Skin Cancer
Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants
Phase 3 N=676 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
N/A N=368 Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors
Melanoma (Skin)
Primary: Sun Protection Habits Index — 2.9; 3 scores on a scale
Phase 2 N=187 Phase IIB TL + YCWP + DC in Melanoma
Melanoma
Primary: Disease Free Survival Assessment — 32; 30; 31; 30 Participants
N/A N=1,000 Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access
Melanoma
Primary: Number of Participants Who Completed SSE at Specified Time Points — 217; 242; 475; 238 Participants — p=<0.001
Phase 3 N=1,383 Evaluation of Pigmented Skin Lesions With MelaFind(R) System
Melanoma
Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05
Phase 1 N=27 An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
Malignant Melanoma
Primary: Maximum Tolerated Dose (MTD) of IMC-20D7S — 20 mg/kg q2w
Phase 2 N=24 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Melanoma · Skin Cancer
Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants
Phase 2 N=98 Melanoma Vaccine With Peptides and Leuprolide
Melanoma
Primary: Number of Participants With T-cell Response to Peptide Vaccine — 6; 1; 12; 19 Participants
N/A N=420 Skin Self-Examination Education During Mammography
Melanoma
Primary: Number of Participants That Performed a Skin Self-Examination at 3-months — 161; 185 Participants — p=0.12
N/A N=54 Enhancing Skin Cancer Early Detection and Treatment in Primary Care
Cutaneous Melanoma
Primary: Change in Clinician Knowledge in Melanoma Risk and Lesion Identification — 72.1; 80.8 score on a scale — p=0.05
Phase 1 N=39 Immunotherapy of Stage III/IV Melanoma Patients
Melanoma
Primary: Change From Baseline in Mean Number of Adverse Events (Serious and Non Serious Events) — 13.40; 18.40; 23.80; 19.60 Number of adverse events
Phase 2 N=90 Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma
Cancer
Primary: Percentage of Agreement Between the Detection of SLNs — 69.7 percentage complete agreement
N/A N=54 Skin Care Behaviors Among Melanoma Survivors and Their Families
Melanoma
Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants
Phase 2 N=52 Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Phase 2 N=64 Ipilimumab + Temozolomide in Metastatic Melanoma
Metastatic Melanoma
Primary: 6-Month Progression-Free Survival (PFS) Rate — 29 participants
Phase 2 N=138 Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Melanoma
Primary: Immunologic Response Rate — 7; 1; 0; 0 Participants
Phase 3 N=3,219 A Study of Vemurafenib in Participants With Metastatic Melanoma
Malignant Melanoma
Primary: Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events…
Phase 2 N=24 Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Melanoma · Skin Cancer · Cancer
Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants
Phase 2 N=10 Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
Skin Cancer · Metastatic Melanoma
Primary: Response — 0; 0; 8; 2 Participants
Phase 2 N=4 Radiation and Combination Immunotherapy for Melanoma
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Phase 2 N=80 Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
Melanoma
Primary: Objective Response Rate (ORR) of PV-10 Treated Lesions — 51.3 percentage of participants
Phase 2 N=3 Intratumoral Injections of LL37 for Melanoma
Melanoma
Primary: Number of Participants With Optimal Biological Dose (OBD) of LL37 Based Upon Toxicity — 2; 1 Participants
Phase 2 N=76 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Intraocular Melanoma · Melanoma (Skin)
Primary: Percentage of Participants With Immune-related Adverse Events (irAEs) — 80.0; 72.0; 65.4 Percentage of participants